Merck KGaA suspends Stimuvax therapeutic cancer vaccine programme
This article was originally published in Scrip
Executive Summary
Merck KGaA has temporarily suspended the clinical development programme for its therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine) after a single patient in one trial developed encephalitis, or acute brain inflammation.